FDA approves GSK RSV vaccine for adults 50 to 59 : compareme

The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.

Related Keywords

United States , United Kingdom , Japan , Americans , British , Phil Dormitzer , Luke Miels , Pfizer , Drug Administration On , Centers For Disease , Drug Administration , Disease Control , Commercial Officer Luke Miels ,